INBRAIN Neuroelectronics

🌟 We're excited that our friends from Vsquared Ventures are once again partners of the Festival der Zukunft by 1E9 and Deutsches Museum, Jun 27-30, Munich! As the pioneer of European deep-tech investment, Vsquared is supporting entrepreneurs that push the boundaries of what's possible! The perfect match for our festival! On June 28 at 12:30 PM, Lise Rechsteiner, PhD, General Partner of Vsquared Ventures, will discuss "Revolutionizing Brain-Computer Interfaces with Graphene" with Carolina Aguilar, CEO of INBRAIN Neuroelectronics. Join us on June 27 at 4:00 PM for our VC Roundtable, "Scaling Up: The Future of European Venture Capital," featuring Dr.-Ing. Herbert Mangesius, General Partner of Vsquared and co-founder of 1E9, alongside Anke Gratz of DTCF | DeepTech & Climate Fonds, Ion Hauer of APEX Ventures, Gonzalo Pérez of Wayra Germany, and Lena Späth of First Momentum Ventures. And on June 28 at 4:00 PM, Herbert will moderate our panel, "Navigating Dual-Use Technologies in a New Geopolitical Era," with Rafaela Kraus from the University of the Bundeswehr Munich, Niclas Sundström of Worthwhile Capital Partners, Sven Weizenegger of Bundeswehr Cyber Innovation Hub and Joshua Western of Space Forge. Don't want to miss them and 150+ other great speakers? Find all information and tickets here: https://lnkd.in/d4qGrnZw #FdZ24 #FestivalderZukunft #DeepTech

An outstanding article today Financial Times highlighting the next generation of BCI for communication and BCI therapeutics we couldn't be more excited about what this decade will bring in helping people with neural related disorders!

Shout out to an insightful panel discussion at the AI for Good summit involving Ryan Field from Kernel, Andreas Forsland from Cognixion, Sid Koudier from Snap Inc. and (of course!) Carolina Aguilar (my CEO and colleague) at INBRAIN Neuroelectronics. Happy to have provided the materials for the INBRAIN's demo showcasing our ML development for high precision brain therapies. This wouldn't have been possible without Matteo Donega, Alejandro Pérez, Marina Saiz Alía, PhD and Aina Maull. such a great team behind! My personal takeaways from the discussion: 1 - Industry seems to have a more symbiotic and fruitful approach regarding the long-standing implantable VS non-implantable BCI confrontation. I moved to industry 3 years ago and by that time academy seemed to be finding a ultimate winner. I think both are valid approaches with different scopes and applications. A bike and a bus are both great means of transport and sometimes you'd like to take your bike in the bus. By confronting applications we may miss great symbiotic applications. So I lean towards the industry point of view. 2 - Following up on the previous. In my opinion, non-implantable BCI are great for point of care rapid and insightful brain function evaluation and life assistance. Their effectiveness lies on bigger coverage, both at the brain, clinical population and disease levels. If you need high precission and targeting specific brain structures and biomarkers for specific and refractive diseases continously and 24/7 implantable and miniaturised is the way forward. Both approaches complement each other very nicely in fact! How can we get the best out of each other inside and outside the clinical practice? 3 - Neurorights. This started as a question from the public and continued off-line with Karen Rommelfanger, PhD. We all agree that patient and stakeholder consent to their data usage should be the ground. But how do you factor in ethics in the design of those data systems and the human decisions in neurotrch organisations? Can an overarching ethical behaviour emerge in companies if all the individuals behave ethically? How can we do this in practice? It looks like a good start that people working in neurotech companies reflect on these questions! Looking forward to come next year with more and for more!

Advancing towards a real minimally invasive BCI therapeutics reality

What to work in a life changing semiconductors development opportunity??? At INBRAIN Neuroelectronics we develop graphene semiconductors technology that powers intelligent precision BCI therapeutics at scale. Join us in lighting up the path to a better neural future!!!

What to work in a life changing semiconductors development opportunity??? At INBRAIN Neuroelectronics we develop graphene semiconductors technology that powers intelligent precision BCI therapeutics at scale. Join us in lighting up the path to a better neural future!!!

Next week is the week of AI for Good! Pablo O. leading our ML developments together with our CEO Carolina Aguilar will be demoing some of the AI work we are developing at INBRAIN Neuroelectronics in delivering real time precision BCI Therapeutics This is a highly anticipated event hosted by the International Telecommunication Union and United Nations Join us!! #ITUaiSummit

Seminconductors are of strategic importance for Spain, the EU and globally. They make crucial components of core emerging technologies such as AI, quantum and digitalization. In the case of INBRAIN Neuroelectronics its application in healthcare brings a revolutionary next gen of BCI therapeutics that allow more precise and effective neuro and bioelectronic therapies without the daring side effects of pharmacology. Jose Antonio Garrido, discusses how we are helping driving semiconductors leadership forward from Barcelona!

🚀 Exciting Times for European Innovation in Silicon Valley! 🚀 I'm thrilled to share that 15 of the most innovative EIC-backed scaleups in health and life sciences participated today in a dedicated European Innovation Council (EIC) Day at Stanford Medicine in Palo Alto, California, in the frame of our new EIC USA Soft Landing Programme pilot. This exceptional event highlights the remarkable potential of European innovation and our commitment to transatlantic collaboration with the purpose of innovation for good. Special thanks to Dean Lloyd Minor, Senior Associate Dean Priya Singh and Managing Director of Strategic Ventures Sean Hennessey-Hsieh for hosting us at the Stanford School of Medicine and to their colleagues. Your support and partnership were invaluable in this event as we work together to accelerate the creation, application and scaleup of breakthrough technologies and game changing innovations. Congratulations to the 15 EIC-backed companies for their outstanding achievements. And big thanks to all who make it possible, in EISMEA EIC BAS, in PwC, in EU Office at SF (Gerard and Joanna) and last but not least to Jillian and her team! #EUeic #Innovation #StanfordMedicine #EuropeanInnovation #GlobalCollaboration #EICSoftlanding #EUUSA #FutureOfInnovation Stéphane Ouaki 🇺🇦🇪🇺 ; Lloyd Minor ; Priya Singh ; Jillian Manus ; Sean Hennessey-Hsieh ; Anna Panagopoulou ; Keith Sequeira ; Michiel Scheffer ; Agnieszka Stasiakowska ; Manuel Mendigutía ; François Brizard ; European Innovation Council and SMEs Executive Agency (EISMEA)

The leadership of the EU Commission, through the European Innovation Council and SMEs Executive Agency (EISMEA) is extraordinary! We have no words to express the level of continuous support and value to the scaling of our innovation. The United States and the EU have the world's largest investment relationship, with nearly $4 trillion in total transatlantic investments! Continue this transformational relationship is essential for global healthcare innovation. Thanks for a fantastic first day of incredible insights!!